Fear mounting that changes to drug pricing in Canada could stifle innovation
Canadian patients and groups representing them are sounding the alarm about recent changes made by the federal government to the way it regulates the cost of patented medicines. Shelves of medication are seen at a pharmacy in Quebec City, Thursday, March 8, 2012. THE CANADIAN PRESS/Jacques Boissinot
Kristy Kirkup, The Canadian Press
Published Thursday, August 22, 2019 2:32PM EDT
Last Updated Thursday, August 22, 2019 5:04PM EDT
OTTAWA -- Some Canadian patients and groups that advocate on their behalf are sounding the alarm about the federal government's recent changes to the way it regulates the cost of patented medicines.
Toronto lawyer and longtime Liberal supporter Chris MacLeod, who lives with cystic fibrosis, said Thursday that it pains him to speak out against the government but he fears lives could be on the line as a result of what he calls a "wholly irresponsible" approach.
"It will be delayed access at best; denial or no access at worst," MacLeod said.
Health Canada recently finalized its long-awaited changes to the process of establishing drug prices, which include providing the Patented Medicines Prices Review Board with the market price of medicines rather than an inflated list price.
The department says the board -- first created 30 years ago to ensure companies don't use monopolies to charge excessive costs -- can now consider whether the drug price actually reflects the value it has for patients.
Earlier this month, board chair Dr. Mitchell Levine also said the body now has the tools and information it needs to meaningfully protect Canadian consumers from excessive prices.
Health Minister Ginette Petitpas Taylor issued a similar statement Thursday, noting the objective of the changes, which have taken three years to implement, was to ultimately lower prices while making sure Canadians get access to the medicines they need.
The government has billed the changes as an effort to establish the groundwork for a national pharmacare program.
MacLeod, however, fears the changes will ultimately drive the list prices down to the point where drug companies will not seek to bring new, game-changing medicines to Canada.
The Canadian Organization for Rare Disorders said it shares MacLeod's concern, adding that while everyone wants to have access to medications at affordable prices, it risks making new therapies less available.
In a letter to Prime Minister Justin Trudeau sent in April prior to the finalization of the regulations, the organization co-signed a letter urging the government to change its course.
"We all want to have access to medicines at affordable prices," the letter said. "However, these proposed changes by the PMPRB will mean that many new therapies will not be available in Canada."
President and CEO Dr. Durhane Wong-Rieger said the organization is worried about the signal the decision sends in terms of Canada's willingness to provide competitive pricing for drugs.
"If we end up being a country that is priced so very low that companies are afraid it is going to impact their ability to actually market elsewhere, they won't come to us first," Wong-Rieger said.